Tenaya Therapeutics, Inc. Operating Income
Tenaya Therapeutics, Inc. (TNYA) reported Operating Income of -$44.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- Tenaya Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$44.09M.
- Tenaya Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$20.07M.
- Tenaya Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$20.77M.
- Tenaya Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$20.94M.
- Tenaya Therapeutics, Inc. operating income (loss) for fiscal 2025 was -$93.33M.
- Tenaya Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$115.95M.
- Tenaya Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$131.19M.
- Tenaya Therapeutics, Inc. operating income (loss) for fiscal 2022 was -$125.62M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$44.09M 10-Q · filed 2026-08-05 | -$64.15M 10-Q · filed 2026-08-05 | -$84.93M derived: sum of 3 quarters · filed 2026-08-05 | -$105.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$20.07M 10-Q · filed 2026-05-06 | -$40.84M derived: sum of 2 quarters · filed 2026-05-06 | -$61.78M derived: sum of 3 quarters · filed 2026-05-06 | -$85.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$20.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$41.71M derived: sum of 2 quarters · filed 2026-03-11 | -$65.79M derived: sum of 3 quarters · filed 2026-08-05 | -$93.33M 10-K · filed 2026-03-11 |
| 2025-09-30 | -$20.94M 10-Q · filed 2025-11-10 | -$45.02M derived: sum of 2 quarters · filed 2026-08-05 | -$72.56M 10-Q · filed 2025-11-10 | -$97.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$24.08M 10-Q · filed 2026-08-05 | -$51.62M 10-Q · filed 2026-08-05 | -$76.27M derived: sum of 3 quarters · filed 2026-08-05 | -$102.98M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$27.54M 10-Q · filed 2026-05-06 | -$52.19M derived: sum of 2 quarters · filed 2026-05-06 | -$78.90M derived: sum of 3 quarters · filed 2026-05-06 | -$109.72M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$24.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | -$51.36M derived: sum of 2 quarters · filed 2026-03-11 | -$82.19M derived: sum of 3 quarters · filed 2026-03-11 | -$115.95M 10-K · filed 2026-03-11 |
| 2024-09-30 | -$26.71M 10-Q · filed 2025-11-10 | -$57.53M derived: sum of 2 quarters · filed 2025-11-10 | -$91.30M 10-Q · filed 2025-11-10 | -$122.74M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$30.82M 10-Q · filed 2025-08-06 | -$64.58M 10-Q · filed 2025-08-06 | -$96.03M derived: sum of 3 quarters · filed 2025-08-06 | -$126.95M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | -$33.76M 10-Q · filed 2025-05-07 | -$65.21M derived: sum of 2 quarters · filed 2025-05-07 | -$96.13M derived: sum of 3 quarters · filed 2025-05-07 | -$131.23M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | -$31.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | -$62.37M derived: sum of 2 quarters · filed 2025-03-10 | -$97.47M derived: sum of 3 quarters · filed 2025-03-10 | -$131.19M 10-K · filed 2025-03-10 |
| 2023-09-30 | -$30.92M 10-Q · filed 2024-11-06 | -$66.02M derived: sum of 2 quarters · filed 2024-11-06 | -$99.75M 10-Q · filed 2024-11-06 | -$134.30M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | -$35.10M 10-Q · filed 2024-08-08 | -$68.83M 10-Q · filed 2024-08-08 | -$103.38M derived: sum of 3 quarters · filed 2024-08-08 | -$134.68M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$33.72M 10-Q · filed 2024-05-14 | -$68.27M derived: sum of 2 quarters · filed 2024-05-14 | -$99.57M derived: sum of 3 quarters · filed 2024-05-14 | -$128.19M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$34.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18 | -$65.85M derived: sum of 2 quarters · filed 2024-03-18 | -$94.47M derived: sum of 3 quarters · filed 2024-03-18 | -$125.62M 10-K · filed 2024-03-18 |
| 2022-09-30 | -$31.30M 10-Q · filed 2023-11-08 | -$59.92M derived: sum of 2 quarters · filed 2023-11-08 | -$91.07M 10-Q · filed 2023-11-08 | -$117.23M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$28.62M 10-Q · filed 2023-08-09 | -$59.77M 10-Q · filed 2023-08-09 | -$85.94M derived: sum of 3 quarters · filed 2023-08-09 | -$104.24M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$31.15M 10-Q · filed 2023-05-10 | -$57.32M derived: sum of 2 quarters · filed 2023-05-10 | -$75.62M derived: sum of 3 quarters · filed 2023-05-10 | -$90.86M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$26.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | -$44.46M derived: sum of 2 quarters · filed 2023-03-08 | -$59.70M derived: sum of 3 quarters · filed 2023-03-08 | -$72.81M 10-K · filed 2023-03-08 |
| 2021-09-30 | -$18.30M 10-Q · filed 2022-11-10 | -$33.54M derived: sum of 2 quarters · filed 2022-11-10 | -$46.64M 10-Q · filed 2022-11-10 | -$56.96M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | -$15.24M 10-Q · filed 2022-08-10 | -$28.34M 10-Q · filed 2022-08-10 | -$38.66M derived: sum of 3 quarters · filed 2022-08-10 | -$49.12M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | -$13.11M 10-Q · filed 2022-05-11 | -$23.43M derived: sum of 2 quarters · filed 2022-05-11 | -$33.88M derived: sum of 3 quarters · filed 2022-05-11 | -$42.75M derived: sum of 4 quarters · filed 2022-05-11 |
| 2020-12-31 | -$10.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | -$20.77M derived: sum of 2 quarters · filed 2022-03-23 | -$29.65M derived: sum of 3 quarters · filed 2022-03-23 | -$38.91M 10-K · filed 2022-03-23 |
| 2020-09-30 | -$10.45M 10-Q · filed 2021-11-10 | -$19.32M derived: sum of 2 quarters · filed 2021-11-10 | -$28.59M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | -$8.87M 10-Q · filed 2021-09-08 | -$18.14M 10-Q · filed 2021-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |